CA3069295A1 - Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf - Google Patents
Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf Download PDFInfo
- Publication number
- CA3069295A1 CA3069295A1 CA3069295A CA3069295A CA3069295A1 CA 3069295 A1 CA3069295 A1 CA 3069295A1 CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A CA3069295 A CA 3069295A CA 3069295 A1 CA3069295 A1 CA 3069295A1
- Authority
- CA
- Canada
- Prior art keywords
- var
- rvwf
- vwf
- infusion
- von willebrand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530027P | 2017-07-07 | 2017-07-07 | |
| US62/530,027 | 2017-07-07 | ||
| PCT/US2018/041320 WO2019010497A1 (en) | 2017-07-07 | 2018-07-09 | TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3069295A1 true CA3069295A1 (en) | 2019-01-10 |
Family
ID=63036433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3069295A Pending CA3069295A1 (en) | 2017-07-07 | 2018-07-09 | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10632176B2 (enExample) |
| EP (2) | EP3648788B1 (enExample) |
| JP (2) | JP7307047B2 (enExample) |
| KR (2) | KR20260037107A (enExample) |
| CN (1) | CN111436193A (enExample) |
| AU (2) | AU2018298233B2 (enExample) |
| BR (1) | BR112020000321A2 (enExample) |
| CA (1) | CA3069295A1 (enExample) |
| CO (1) | CO2020001322A2 (enExample) |
| DK (1) | DK3648788T3 (enExample) |
| ES (1) | ES2986574T3 (enExample) |
| FI (1) | FI3648788T5 (enExample) |
| MX (1) | MX2025012580A (enExample) |
| PL (1) | PL3648788T3 (enExample) |
| PT (1) | PT3648788T (enExample) |
| WO (1) | WO2019010497A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3648788T5 (fi) | 2017-07-07 | 2024-09-09 | Takeda Pharmaceuticals Co | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää |
| JP7326246B2 (ja) | 2017-07-07 | 2023-08-15 | 武田薬品工業株式会社 | 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法 |
| US20220395560A1 (en) * | 2019-02-01 | 2022-12-15 | Takeda Pharmaceutical Company Limited | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) |
| EA202192140A1 (ru) * | 2019-02-01 | 2021-12-15 | Такеда Фармасьютикал Компани Лимитед | СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) |
| WO2021032646A1 (en) * | 2019-08-16 | 2021-02-25 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| WO1986006096A1 (en) | 1985-04-11 | 1986-10-23 | The Children's Medical Center Corporation | Von willebrand factor |
| US8597910B1 (en) | 1985-04-11 | 2013-12-03 | Children's Medical Center Corporation | DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| US6005077A (en) | 1995-11-10 | 1999-12-21 | Immuno Aktiengesellschaft | Use of von willebrand factor and pharmaceutical formulation |
| AT403764B (de) | 1996-03-15 | 1998-05-25 | Immuno Ag | Stabiler faktor viii/vwf-komplex |
| AT405403B (de) | 1997-02-27 | 1999-08-25 | Immuno Ag | Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie |
| AT406373B (de) | 1997-02-27 | 2000-04-25 | Immuno Ag | Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie |
| AT405485B (de) | 1997-05-28 | 1999-08-25 | Immuno Ag | Eine das vwf-propeptid enthaltende pharmazeutische präparation |
| US6531577B1 (en) | 1997-12-15 | 2003-03-11 | Hemasure Denmark A/S | von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations |
| WO2004039337A2 (en) | 2002-10-31 | 2004-05-13 | Protein Design Labs, Inc. | Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization |
| WO2005012354A1 (en) | 2003-07-31 | 2005-02-10 | Zlb Behring Gmbh | Method for extending the half-life of fviii |
| EP1593388A1 (en) | 2004-05-05 | 2005-11-09 | ZLB Behring GmbH | Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers |
| US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| AU2005322067B8 (en) | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| ES2474573T3 (es) | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| PL2167117T3 (pl) | 2007-06-13 | 2013-01-31 | Csl Behring Gmbh | Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| EP2244814B1 (en) | 2007-12-28 | 2021-06-02 | Takeda Pharmaceutical Company Limited | Recombinant vwf formulations |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| EP2349314B1 (en) | 2008-10-21 | 2013-02-27 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| US20110072524A1 (en) | 2009-08-04 | 2011-03-24 | Baxter International Inc. | Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A |
| EA202090067A3 (ru) | 2010-07-08 | 2020-07-31 | Баксалта Инкорпорейтид | Способ получения рекомбинантного adamts13 в культуре клеток |
| CN103732244A (zh) | 2011-06-10 | 2014-04-16 | 巴克斯特国际公司 | 通过施用重组vwf治疗凝血疾病 |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| FI3648788T5 (fi) | 2017-07-07 | 2024-09-09 | Takeda Pharmaceuticals Co | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää |
-
2018
- 2018-07-09 FI FIEP18746458.1T patent/FI3648788T5/fi active
- 2018-07-09 CN CN201880057599.9A patent/CN111436193A/zh active Pending
- 2018-07-09 ES ES18746458T patent/ES2986574T3/es active Active
- 2018-07-09 BR BR112020000321-2A patent/BR112020000321A2/pt unknown
- 2018-07-09 KR KR1020267002897A patent/KR20260037107A/ko active Pending
- 2018-07-09 KR KR1020207003264A patent/KR102921337B1/ko active Active
- 2018-07-09 EP EP18746458.1A patent/EP3648788B1/en active Active
- 2018-07-09 WO PCT/US2018/041320 patent/WO2019010497A1/en not_active Ceased
- 2018-07-09 EP EP24176324.2A patent/EP4424366A3/en active Pending
- 2018-07-09 US US16/030,659 patent/US10632176B2/en active Active
- 2018-07-09 DK DK18746458.1T patent/DK3648788T3/da active
- 2018-07-09 PT PT187464581T patent/PT3648788T/pt unknown
- 2018-07-09 CA CA3069295A patent/CA3069295A1/en active Pending
- 2018-07-09 PL PL18746458.1T patent/PL3648788T3/pl unknown
- 2018-07-09 JP JP2020500617A patent/JP7307047B2/ja active Active
- 2018-07-09 AU AU2018298233A patent/AU2018298233B2/en active Active
-
2020
- 2020-01-08 MX MX2025012580A patent/MX2025012580A/es unknown
- 2020-02-06 CO CONC2020/0001322A patent/CO2020001322A2/es unknown
- 2020-02-26 US US16/802,118 patent/US10905746B2/en active Active
- 2020-12-01 US US17/108,562 patent/US11529395B2/en active Active
-
2022
- 2022-12-06 US US18/062,534 patent/US12016904B2/en active Active
-
2023
- 2023-06-29 JP JP2023106554A patent/JP7641327B2/ja active Active
-
2024
- 2024-06-12 US US18/741,650 patent/US20240316160A1/en active Pending
-
2025
- 2025-07-11 AU AU2025205392A patent/AU2025205392A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12016904B2 (en) | Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF | |
| AU2025205070A1 (en) | Treatment Of Patients With Severe Von Willebrand Disease Undergoing Elective Surgery By Administration Of Recombinant VWF | |
| US12128090B2 (en) | Methods of prophylactic treatment using recombinant VWF (rVWF) | |
| US20220395560A1 (en) | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) | |
| HK40115617A (en) | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf | |
| US20230398188A1 (en) | Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf | |
| RU2774720C2 (ru) | ЛЕЧЕНИЕ ЖЕЛУДОЧНО-КИШЕЧНОГО КРОВОТЕЧЕНИЯ У ПАЦИЕНТОВ С ТЯЖЕЛОЙ ФОРМОЙ БОЛЕЗНИ ФОН ВИЛЛЕБРАНДА ПУТЕМ ВВЕДЕНИЯ РЕКОМБИНАНТНОГО ФфВ | |
| HK40029176A (en) | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf | |
| HK40029176B (en) | Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf | |
| EA047451B1 (ru) | СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) | |
| HK40029186B (en) | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf | |
| HK40029186A (en) | Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20221002 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240702 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250115 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250115 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250116 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250116 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250625 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251009 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: T-6-6-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260609 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: T-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260618 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: T-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260618 |